The Abu Dhabi Stem Cells Centre (ADSCC) has fast gained popularity for its breakthrough in the implementation of the Abu Dhabi Bone Marrow Transplant programme (AD-BMT). The programme, first introduced in July last year, has successfully helped to treat a total of six patients with blood malignancies, all of whom are recovering well. The brainchild of ADSCC, the AD-BMT was set up to provide the highest standard of care in the field of Hematopoietic Stem Cells Transplant.
The programme kick started in August last year, and has treated patients with different types of blood malignancies such as Multiple Myeloma, Plasma Cell Leukemia, Large Diffuse B-Cell Lymphoma and Hodgkin Lymphoma. The treatment duration has varied for each patient, ranging from 19 days to up to one month.
The programme’s laudable clinical results have allowed ADSCC to look towards gaining international recognition. Taking it a step further, a report on ADSCC’s official website read it will be adopting a comprehensive approach to make sure of the proper use and implementation of technology, sustainable and eco-friendly practices and a commitment to innovation and translational research. its expansion to offer other procedures and treatments. Moreover, the AD-BMT programme will continue to admit patients for treatment and has plans on expanding its capacity to be able to treat more than one patient at the same time, with the larger goal being able to treat not only patients with hematological conditions, but also patients with autoimmune diseases and primary immune deficiencies.